argenx SE

    Jurisdiction
    Netherlands
    LEI
    7245009C5FZE6G9ODQ71
    ISIN
    US04016X1019 (ARGX)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    53 / 100
    Better than peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    €730.37 5.9% undervalued
    Fundamental strength relative to industry (Mohanram G-Value)
    2 / 7

    Profile

    argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Read full profile

    Fundamentals

    Net revenue
    €2.43B
    Gross margin
    92.7%
    EBIT
    €51.24M
    EBIT margin
    2.1%
    Net income
    €763.30M
    Net margin
    31.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €4.59B +88.7% €1.42B +85.6%
    €5.54B +20.8% €1.90B +34.0%
    €6.55B +18.2% €2.61B +37.5%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    No insider transactions in the last 90 days. View older insider transactions

    Earnings Calls

    Earnings Calls

    Latest earnings call: October 31, 2023 (Q3 2023)

    Add to watchlist

    Notifications